Education & Training

Most Recent Trainings

• Share

  Treatment of Opioid Use Disorder in the Emergency Department: Should it be a Choice?

  Target Audience(s): Nurses, Pharmacists, Physician Assistants, Physicians

  Organization(s): American Academy of Addiction Psychiatry, American Psychiatric Association

  Topic(s): Administrative, Buprenorphine, Overdose, Practice Issues, Treatment Modalities, Withdrawal

  Presenter(s): Gail D’Onofrio, MD

  This webinar will focus on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, will discuss her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine will be discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships will be outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation of buprenorphine effectively reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
• Share

  Team-Based Care to Address Psychiatric and Physical Health Co-morbidities in Persons with Opioid Use Disorders: Responding to Chicago’s Opioid Crisis

  Target Audience(s): Administrative Staff, Nurses, Pharmacists, Physician Assistants, Physicians

  Organization(s): National Council for Behavioral Health

  Topic(s): Administrative, Buprenorphine, Language and Treating OUD, Medical / Special Populations, Naloxone, Overdose, Practice Issues, Psychiatric Co-morbidity, Special Topics, Withdrawal

  Presenter(s): Steve Weinstein, MD; Tim Devitt, Psy.D, MS.Ed; J. Wesley Cook, DO; Nicholas Chien, MD; Ruchi Fitzgerald, MD, FAAFP

  According to provisional data from the Centers for Disease Control and Prevention (CDC), over 81,000 drug overdose deaths occurred in the United States in the 12 months ending in May 2020, the highest number of overdose deaths ever recorded in a 12-month period. Most of these deaths are driven by the misuse of prescription and illicit opioids. Research also suggests that a significant number of people with an opioid use disorder also have a co-occurring psychiatric disorder as well as other physical health conditions, making engagement and care more complex. Please join us as we discuss how one treatment program in Chicago uses a team-based care approach to engage and address the psychiatric and health care needs of people with opioid use disorders.
• Share

  Methamphetamine in the Age of Fentanyl: Toxicities and Pharmacotherapies

  Target Audience(s): Nurses, Pharmacists, Physician Assistants, Physicians, Psychologists

  Organization(s): American Academy of Addiction Psychiatry, American Psychiatric Association

  Topic(s): Buprenorphine, Medical / Special Populations, Overdose, Psychiatric Co-morbidity, Special Topics, Treatment Modalities

  Presenter(s): Phillip Coffin, MD

  Morbidity and mortality related to methamphetamine use have been escalating dramatically. While these shifts began before fentanyl was established as a street opioid, trends have become even more profoundly concerning as fentanyl has come to dominate most markets around the United States. Treatment of methamphetamine use disorder is limited, with strong data for contingency management and modest data for a growing number of medications. This activity will review available treatment options and future possibilities for addressing an escalating trend in methamphetamine mortality and morbidity. Since the concept of methamphetamine or stimulant overdose is often overlooked or difficult to assess, especially in comparison to the trademark signs of opioid overdose like respiratory depression, this webinar will illustrate the symptoms of acute stimulant toxicity events and the medical interventions necessary to treat them. Learners will gain a better understanding of the intersections between stimulant use and opioid use disorder and how to best recognize overdose events related to polysubstance use.